NTLA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Intellia Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business and Pipeline Updates

Nov 5, 2026

8-K

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvo-z in Hereditary Angioedema

Sep 8, 2026

8-K

Intellia Therapeutics Secures $400 Million Non-Dilutive Debt Facility with OrbiMed

Sep 4, 2026

8-K

Intellia Therapeutics Reports Q2 2026 Financial Results and Clinical Progress for Lonvo-z and Nex-z

Aug 6, 2026

8-K

Intellia Therapeutics Reports Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Hereditary Angioedema

Jun 15, 2026

8-K

Intellia Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 10, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Apr 29, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $150,000,000 | Bank: Jefferies, Goldman Sachs & Co. LLC, Citigroup

Apr 27, 2026

424B5

March 2026 ATM | Offering amount: $400,000,000 | Shares: 28,011,204 | Bank: Jefferies LLC

Mar 2, 2026

424B5

ATM | Offering amount: $375,727,167

Feb 26, 2024

424B5

ATM | Offering amount: $375,727,167

Feb 23, 2024

424B5

SHELF OFFERING | Shares amount: 6,550,219 | Share price: $45.80 | Offering amount: $300,000,030.00 | Bank: Goldman Sachs & Co. LLC

Dec 1, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8